U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K/A
Amendment No. 1
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2023
Commission File Number: 001-39137
AnPac Bio-Medical Science Co., Ltd.
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXPLANATORY NOTE
This Amendment No. 1 (“Amendment No. 1”) amends the Current Report on Form 6-K of Anpac Bio-Medical Science Co., Ltd., originally filed with the Securities and Exchange Commission on April 4, 2023 (the “Original 6-K”). This Amendment No.1 is being filed to correct several typographical errors in Exhibits 5.1, 5.2 and 10.1. Other than the foregoing exhibits, no other items of the Original 6-K are being amended and this Amendment No. 1 does not reflect any events occurring after the filing of the Original 6-K.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | AnPac Bio-Medical Science Co., Ltd. |
| | | |
| | By: | /s/ Haohan Xu |
| | Name: | Haohan Xu |
| | Title: | Co-Chief Executive Officer |
Dated: April 5, 2023
2
